Figure 4. Tumors with low CDKN2A expression have decreased expression of SASP. (A) Percentage of SASP genes significantly upregulated and downregulated in CDKN2A-low (i.e., p16-low) expressing tumors when compared to CDKN2A-high (i.e., p16-high) expressing tumors. (B) Negatively enriched SASP term among the six studied tumor types in Gene Set Enrichment Analysis (GSEA) between CDKN2A-low and CDKN2A-high expressing tumors. SKCM (skin cutaneous melanoma), PAAD (pancreatic adenocarcinoma), COADREAD (colorectal adenocarcinoma), MESO (mesothelioma), BLCA (bladder urothelial carcinoma), GBM (glioblastoma multiforme), NES (negative enrichment score). (C) Correlation between CDKN2A and LMNB1 expression for each tumor type. Data are shown as Log2 of RSEM. Coefficient of correlation (r) and p-value were calculated using Pearson’s correlation.